Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May 30;15(5):2882-2884.
doi: 10.21037/jtd-22-1862. Epub 2023 Apr 23.

Is machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images associated with outcomes of immunotherapy in patients with NSCLC?

Kentaro Inamura  1   2 , Yasuyuki Shigematsu  1   2
Affiliations
Comment

Is machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images associated with outcomes of immunotherapy in patients with NSCLC?

Kentaro Inamura et al. J Thorac Dis. .
No abstract available

Keywords: Artificial intelligence; digital pathology; immune checkpoint inhibitor (ICI); non-small cell lung cancer (NSCLC); tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1862/coif). KI serves as an unpaid editorial board member of Journal of Thoracic Disease from February 2023 to January 2025. The other author has no conflicts of interest to declare.

Comment on

References

    1. Rakaee M, Adib E, Ricciuti B, et al. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC. JAMA Oncol 2023;9:51-60. 10.1001/jamaoncol.2022.4933 - DOI - PMC - PubMed
    1. Corredor G, Wang X, Zhou Y, et al. Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res 2019;25:1526-34. 10.1158/1078-0432.CCR-18-2013 - DOI - PMC - PubMed
    1. Angelova M, Mlecnik B, Vasaturo A, et al. Evolution of Metastases in Space and Time under Immune Selection. Cell 2018;175:751-765.e16. 10.1016/j.cell.2018.09.018 - DOI - PubMed
    1. Lang KS, Georgiev P, Recher M, et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest 2006;116:2456-63. 10.1172/JCI28349 - DOI - PMC - PubMed
    1. Lamberti G, Spurr LF, Li Y, et al. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol 2020;31:807-14. 10.1016/j.annonc.2020.02.017 - DOI - PubMed